SS Innovations International, Inc. reported a 192.5% revenue increase to $12.8 million in Q3 2025, with a net loss of $3.7 million. The SSi Mantra surgical robotic system installations totaled 27, up 350.0% from the previous year. For the first nine months of 2025, revenue rose 123.0% to $28.0 million, with a net loss of $9.7 million.

As of September 30, 2025, SS Innovations had no long-term debt and $5.7 million in cash and equivalents. The SSi Mantra surgical robotic system had a cumulative installed base of 127 in seven countries, with over 6,000 surgeries performed, including 56 telesurgeries and 319 cardiac procedures.

CEO Dr. Sudhir Srivastava highlighted strong revenue growth in Q3 2025, driven by higher SSi Mantra 3 system sales. The company aims to democratize access to robotic surgery globally, with regulatory approvals in seven countries. SS Innovations completed a human factors validation study at Johns Hopkins Hospital, a key step towards FDA approval.

Select business highlights in Q3 2025 included the first robotic telesurgery, first pediatric pyeloplasty telesurgery, and the appointment of Naveen Kumar Amar as CFO. The company aims to expand globally and provide cost-effective surgical robotic solutions.

In Q3 2025, SS Innovations reported revenue of $12.8 million, with system sales up 194.9%. The SSi Mantra installations reached 27, with a cumulative base of 127 across various specialties. For the first nine months of 2025, revenue increased to $28.0 million, with 63 system installations and 3,259 surgeries.

SS Innovations is set to participate in upcoming investor conferences, including the UBS Global Healthcare Conference and the Stifel 2025 Healthcare Conference. The company’s innovative surgical robotic technologies aim to make robotic surgery accessible and affordable worldwide, with a range of advanced features.

Read more at GlobeNewswire: SS Innovations Reports Third Quarter 2025 Financial